Please Note: This trial is no longer enrolling new participants
Phase 1 Study of the Safety and Tolerability of RAD202, a Rhenium-188 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients with Inoperable Locally Advanced and/or Metastatic Breast Cancer
Protocol No. | CTO-RAD202-2022-0001 | Scope | National |
---|---|---|---|
Principal Investigator | Kathy Miller | Treatment Type | Treatment |
Age Group | Adult | Phase | Phase I |